chr16-68122469-T-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_173165.3(NFATC3):c.586T>A(p.Leu196Met) variant causes a missense change. The variant allele was found at a frequency of 0.0000273 in 1,613,860 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000029 ( 0 hom. )
Consequence
NFATC3
NM_173165.3 missense
NM_173165.3 missense
Scores
3
7
9
Clinical Significance
Conservation
PhyloP100: 3.85
Genes affected
NFATC3 (HGNC:7777): (nuclear factor of activated T cells 3) The product of this gene is a member of the nuclear factors of activated T cells DNA-binding transcription complex. This complex consists of at least two components: a preexisting cytosolic component that translocates to the nucleus upon T cell receptor (TCR) stimulation and an inducible nuclear component. Other members of this family participate to form this complex also. The product of this gene plays a role in the regulation of gene expression in T cells and immature thymocytes. Several transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Nov 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.13241228).
BS2
High AC in GnomAdExome4 at 42 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NFATC3 | NM_173165.3 | c.586T>A | p.Leu196Met | missense_variant | 2/10 | ENST00000346183.8 | NP_775188.1 | |
NFATC3 | NM_004555.4 | c.586T>A | p.Leu196Met | missense_variant | 2/11 | NP_004546.1 | ||
NFATC3 | NM_173163.3 | c.586T>A | p.Leu196Met | missense_variant | 2/11 | NP_775186.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NFATC3 | ENST00000346183.8 | c.586T>A | p.Leu196Met | missense_variant | 2/10 | 1 | NM_173165.3 | ENSP00000300659.5 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152006Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
2
AN:
152006
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000152 AC: 38AN: 250298Hom.: 0 AF XY: 0.0000960 AC XY: 13AN XY: 135358
GnomAD3 exomes
AF:
AC:
38
AN:
250298
Hom.:
AF XY:
AC XY:
13
AN XY:
135358
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000287 AC: 42AN: 1461854Hom.: 0 Cov.: 35 AF XY: 0.0000206 AC XY: 15AN XY: 727222
GnomAD4 exome
AF:
AC:
42
AN:
1461854
Hom.:
Cov.:
35
AF XY:
AC XY:
15
AN XY:
727222
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152006Hom.: 0 Cov.: 31 AF XY: 0.0000135 AC XY: 1AN XY: 74238
GnomAD4 genome
AF:
AC:
2
AN:
152006
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
74238
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
14
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 20, 2024 | The c.586T>A (p.L196M) alteration is located in exon 2 (coding exon 2) of the NFATC3 gene. This alteration results from a T to A substitution at nucleotide position 586, causing the leucine (L) at amino acid position 196 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
.;.;T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;M;M;M
PrimateAI
Pathogenic
D
PROVEAN
Benign
.;N;N;N
REVEL
Benign
Sift
Pathogenic
.;D;D;D
Sift4G
Uncertain
D;D;D;D
Polyphen
1.0, 1.0
.;D;D;.
Vest4
MutPred
Gain of catalytic residue at V192 (P = 0.0438);Gain of catalytic residue at V192 (P = 0.0438);Gain of catalytic residue at V192 (P = 0.0438);Gain of catalytic residue at V192 (P = 0.0438);
MVP
MPC
0.42
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at